Raymond James & Associates Sarepta Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 25,713 shares of SRPT stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,713

Previous 21,648 18.78%

Holding current value

$2.92 Million

Previous $3.42 Million 6.11%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$124.33 - $156.75 $505,401 - $637,188	4,065 Added 18.78%	25,713 $3.21 Million
Q2 2024 Jul 19, 2024	BUY	$113.33 - $163.85 $1.02 Million - $1.47 Million	8,992 Added 71.05%	21,648 $3.42 Million
Q1 2024 Apr 22, 2024	BUY	$93.7 - $141.53 $267,700 - $404,351	2,857 Added 29.16%	12,656 $1.64 Million
Q4 2023 Jan 16, 2024	SELL	$67.31 - $124.76 $36,280 - $67,245	-539 Reduced 5.21%	9,799 $944,000
Q3 2023 Oct 24, 2023	SELL	$102.5 - $123.59 $288,742 - $348,153	-2,817 Reduced 21.41%	10,338 $1.25 Million
Q2 2023 Jul 25, 2023	SELL	$106.4 - $157.19 $19,364 - $28,608	-182 Reduced 1.36%	13,155 $1.51 Million
Q1 2023 Apr 14, 2023	BUY	$117.53 - $155.99 $194,982 - $258,787	1,659 Added 14.21%	13,337 $1.84 Million
Q4 2022 Feb 08, 2023	SELL	$100.86 - $132.13 $248,720 - $325,832	-2,466 Reduced 17.43%	11,678 $1.51 Million
Q3 2022 Oct 25, 2022	SELL	$75.71 - $119.24 $11,205 - $17,647	-148 Reduced 1.04%	14,144 $1.56 Million
Q2 2022 Aug 12, 2022	BUY	$62.69 - $88.44 $9,654 - $13,619	154 Added 1.09%	14,292 $1.07 Million
Q1 2022 May 11, 2022	BUY	$63.15 - $90.42 $32,964 - $47,199	522 Added 3.83%	14,138 $1.1 Million
Q4 2021 Feb 08, 2022	BUY	$77.28 - $99.42 $438,564 - $564,208	5,675 Added 71.46%	13,616 $1.23 Million
Q3 2021 Nov 02, 2021	SELL	$65.97 - $92.48 $8,708 - $12,207	-132 Reduced 1.64%	7,941 $734,000
Q2 2021 Aug 11, 2021	SELL	$69.38 - $86.75 $26,572 - $33,225	-383 Reduced 4.53%	8,073 $628,000
Q1 2021 May 14, 2021	SELL	$72.25 - $168.95 $1.99 Million - $4.65 Million	-27,526 Reduced 76.5%	8,456 $630,000
Q4 2020 Feb 12, 2021	BUY	$125.56 - $178.74 $318,671 - $453,642	2,538 Added 7.59%	35,982 $6.14 Million
Q3 2020 Nov 04, 2020	BUY	$127.12 - $172.34 $1.29 Million - $1.75 Million	10,176 Added 43.73%	33,444 $4.7 Million
Q2 2020 Jul 28, 2020	BUY	$93.0 - $171.7 $144,150 - $266,135	1,550 Added 7.14%	23,268 $3.73 Million
Q1 2020 Apr 21, 2020	SELL	$82.38 - $131.64 $340,641 - $544,331	-4,135 Reduced 15.99%	21,718 $2.12 Million
Q4 2019 Feb 12, 2020	BUY	$76.53 - $135.58 $189,029 - $334,882	2,470 Added 10.56%	25,853 $3.34 Million
Q3 2019 Nov 07, 2019	BUY	$72.81 - $156.91 $374,971 - $808,086	5,150 Added 28.25%	23,383 $1.76 Million
Q2 2019 Aug 06, 2019	BUY	$112.21 - $151.95 $70,467 - $95,424	628 Added 3.57%	18,233 $2.77 Million
Q1 2019 May 06, 2019	BUY	$106.67 - $151.68 $177,818 - $252,850	1,667 Added 10.46%	17,605 $2.1 Million
Q4 2018 Feb 11, 2019	SELL	$97.32 - $148.76 $710,046 - $1.09 Million	-7,296 Reduced 31.4%	15,938 $1.74 Million
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $836,919 - $1.17 Million	7,258 Added 45.43%	23,234 $3.75 Million
Q2 2018 Aug 14, 2018	SELL	$71.74 - $153.69 $597,881 - $1.28 Million	-8,334 Reduced 34.28%	15,976 $2.11 Million
Q1 2018 May 14, 2018	SELL	$54.02 - $82.27 $2,322 - $3,537	-43 Reduced 0.18%	24,310 $1.8 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $25,153 - $29,964	-528 Reduced 2.12%	24,353 $1.36 Million
Q3 2017 Nov 13, 2017	BUY	$35.73 - $47.15 $512,403 - $676,178	14,341 Added 136.06%	24,881 $1.13 Million
Q2 2017 Aug 14, 2017	BUY	N/A	10,540	10,540 $355,000

Others Institutions Holding SRPT

# of Institutions

525

Shares Held

84.4M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.96B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Sarepta Therapeutics, Inc. Transaction History